Re: Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020; 36(1):33–41. Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36(1):43–50.
dc.authorscopusid | 26030049400 | |
dc.authorscopusid | 56995794400 | |
dc.authorscopusid | 24172964200 | |
dc.contributor.author | Umit E.G. | |
dc.contributor.author | Kara O. | |
dc.contributor.author | Adiguzel C. | |
dc.date.accessioned | 2024-06-12T10:25:13Z | |
dc.date.available | 2024-06-12T10:25:13Z | |
dc.date.issued | 2020 | |
dc.description.abstract | [No abstract available] | en_US |
dc.identifier.doi | 10.1080/03007995.2020.1729109 | |
dc.identifier.issn | 0300-7995 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 32090625 | en_US |
dc.identifier.scopus | 2-s2.0-85083042446 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 607 | en_US |
dc.identifier.uri | https://doi.org/10.1080/03007995.2020.1729109 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/16243 | |
dc.identifier.volume | 36 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Taylor and Francis Ltd | en_US |
dc.relation.ispartof | Current Medical Research and Opinion | en_US |
dc.relation.publicationcategory | Diğer | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Ganciclovir; Valaciclovir; Virus Dna; Acute Leukemia; Adult; Aged; Allogeneic Hematopoietic Stem Cell Transplantation; Cytomegalovirus Infection; Female; Hospital Readmission; Hospitalization Cost; Human; Infection Prevention; Letter; Lymphoma; Major Clinical Study; Male; Myeloablative Conditioning; Myeloma; Nonhuman; Reduced Intensity Conditioning; Retrospective Study; Survival; Virus Reactivation; Cost; Cytomegalovirus; Cytomegalovirus Infection; Hematopoietic Stem Cell Transplantation; Hospitalization; Costs And Cost Analysis; Cytomegalovirus; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans | en_US |
dc.title | Re: Schelfhout J, Bonafede M, Cappell K, et al. Impact of cytomegalovirus complications on resource utilization and costs following hematopoietic stem cell transplant. Curr Med Res Opin. 2020; 36(1):33–41. Schelfhout J, Brown H, House JA, Raval AD. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. Curr Med Res Opin. 2020;36(1):43–50. | en_US |
dc.type | Letter | en_US |